GSK confirmed today that it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court.

As a result of this agreement, the case, which was scheduled to go to trial on April 2, 2024, will be dismissed.

GSK states that this settlement is intended to 'avoid the distractions of protracted litigation in this matter' and otherwise 'admits no liability'.

The laboratory also assures that it will continue 'to defend itself vigorously on the basis of facts and science in all other Zantac cases.'


Copyright (c) 2024 CercleFinance.com. All rights reserved.